Humacyte, Inc.
HUMA
$1.47
-$0.03-2.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -41.78% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.78% | -- | |||
| Cost of Revenue | 42.75% | -24.65% | |||
| Gross Profit | -45.65% | 27.15% | |||
| SG&A Expenses | -4.02% | 9.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.70% | -15.62% | |||
| Operating Income | -28.22% | 17.46% | |||
| Income Before Tax | -196.22% | 286.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -196.22% | 286.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -196.22% | 286.91% | |||
| EBIT | -28.22% | 17.46% | |||
| EBITDA | -30.51% | 18.75% | |||
| EPS Basic | -181.64% | 279.99% | |||
| Normalized Basic EPS | -157.26% | 61.51% | |||
| EPS Diluted | -182.50% | 278.11% | |||
| Normalized Diluted EPS | -157.77% | 61.59% | |||
| Average Basic Shares Outstanding | 18.09% | 3.66% | |||
| Average Diluted Shares Outstanding | 17.85% | 3.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||